APELLIS PHARMACEUTICALS, INC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2008-01-01

Employees: 706

Market Cap: $4.8B

Website: http://www.apellis.com

Clinical Trials

Geographic Atrophy Long-Terms Outcomes Study

Completed

Conditions: Geographic Atrophy

First Posted Date: 2024-07-12

Last Posted Date: 2024-07-12

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 255

Registration Number: NCT06499571

Locations: 🇫🇷
Centre Hospitalier de la Croix Rousse, Lyon Cedex 04, Rhone, France
🇦🇺
Sydney West Retina, Westmead, New South Wales, Australia
🇮🇹
Azienda Socio Sanitaria Territoriale Fatebenefratelli (Presidio Ospedale Sacco), Milano, Italy

and more 2 locations

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Recruiting

Conditions: Geographic Atrophy

Interventions: Drug: Pegcetacoplan

First Posted Date: 2023-12-08

Last Posted Date: 2024-05-31

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 300

Registration Number: NCT06161584

Locations: 🇺🇸
Retinal Consultants Medical Group Inc (01-008), Modesto, California, United States
🇺🇸
Retina-Vitreous Associates Medical Group (01-020), Beverly Hills, California, United States
🇺🇸
Long Island Vitreoretinal Consultants (01-013), Westbury, New York, United States

and more 28 locations

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Phase 3

Active, not recruiting

Conditions: C3 Glomerulopathy
DDD
Membranoproliferative Glomerulonephritis
Complement 3 Glomerulopathy
Membranoproliferative Glomerulonephritis (MPGN)
IC-MPGN
C3 Glomerulonephritis
Complement 3 Glomerulonephritis
Dense Deposit Disease
Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Interventions: Drug: Pegcetacoplan

First Posted Date: 2023-04-12

Last Posted Date: 2024-03-12

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 100

Registration Number: NCT05809531

Locations: 🇧🇷
Santa Casa de Misericordia de Belo Horizonte (55017), Belo Horizonte, Minas Gerais, Brazil
🇨🇭
CHUV Lausanne (41002), Lausanne, Switzerland
🇧🇷
HC UNESP Botucatu (55010), Botucatu, Brazil

and more 23 locations

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Phase 3

Active, not recruiting

Conditions: C3G
Membranoproliferative Glomerulonephritis (MPGN)
IC-MPGN
Complement 3 Glomerulopathy
Complement 3 Glomerulonephritis
Dense Deposit Disease
DDD
C3 Glomerulopathy
Complement 3 Glomerulopathy (C3G)
C3 Glomerulonephritis

Interventions: Other: Placebo
Drug: Pegcetacoplan

First Posted Date: 2021-10-05

Last Posted Date: 2024-07-26

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 90

Registration Number: NCT05067127

Locations: 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
🇳🇱
Emma Kinderziekenhuis, Amsterdam UMC, Amsterdam, Netherlands
🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands

and more 120 locations

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 2

Recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal Hemoglobinuria

Interventions: Drug: Pegcetacoplan

First Posted Date: 2021-05-26

Last Posted Date: 2022-07-20

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 12

Registration Number: NCT04901936

Locations: 🇹🇭
Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand
🇨🇿
Motol University Hospital, Prague, Czechia
🇺🇸
Children's Hospital of Atlanta, Atlanta, Georgia, United States

and more 7 locations

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

Phase 3

Active, not recruiting

Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration

Interventions: Drug: PEGCETACOPLAN (APL-2)

First Posted Date: 2021-02-25

Last Posted Date: 2024-06-26

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 1200

Registration Number: NCT04770545

Locations: 🇺🇸
Northwestern Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States

and more 164 locations

C3G/Primary IC-MPGN EAP

Conditions: C3G
IC-MPGN
C3 Glomerulopathy
C3 Glomerulonephritis
Complement 3 Glomerulopathy
Complement 3 Glomerulopathy (C3G)
Complement 3 Glomerulonephritis
Dense Deposit Disease
DDD
Membranoproliferative Glomerulonephritis

First Posted Date: 2021-01-28

Last Posted Date: 2024-07-26

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Registration Number: NCT04729062

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Terminated

Conditions: Amyotrophic Lateral Sclerosis
Motor Neuron Disease

Interventions: Drug: Pegcetacoplan (APL-2)
Other: Placebo

First Posted Date: 2020-10-08

Last Posted Date: 2024-02-14

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 249

Registration Number: NCT04579666

Locations: 🇦🇺
Brain and Mind Centre, Camperdown, New South Wales, Australia
🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Hospital for Special Surgery, New York, New York, United States

and more 57 locations

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

Phase 2

Active, not recruiting

Conditions: Renal Transplant
Dense Deposit Disease (DDD)
Membranoproliferative Glomerulonephritis (MPGN)
Complement 3 Glomerulonephritis
Membranoproliferative Glomerulonephritis
C3 Glomerulonephritis
C3G
Complement 3 Glomerulopathy
Complement 3 Glomerulopathy (C3G)
Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Interventions: Drug: Pegcetacoplan

First Posted Date: 2020-10-01

Last Posted Date: 2024-03-06

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 13

Registration Number: NCT04572854

Locations: 🇮🇹
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Italy
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States

and more 22 locations

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

Phase 1

Completed

Conditions: Covid-19
Ards
Coronavirus
Coronavirus Infection
Severe Acute Respiratory Syndrome
Severe Acute Respiratory Syndrome Coronavirus 2
Sars-CoV2
COVID
Acute Respiratory Distress Syndrome

Interventions: Other: Vehicle Control
Drug: APL-9

First Posted Date: 2020-05-26

Last Posted Date: 2022-03-23

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 72

Registration Number: NCT04402060

Locations: 🇺🇸
Rutgers University - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸
Westchester General Hospital, Miami, Florida, United States

and more 21 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy